Dossier assessment
Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Report documents
-
Dossier assessment
Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Additional information
Federal Joint Committee (G-BA)
2016-12-01 A G-BA decision was published.
Project details
- Project no.
- G16-02
- Commission
- Commission awarded on 26.05.2016 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
In accordance with § 35a (para. 1, sentence 10) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Daratumumab report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.
Connected Projects
-
Dossier assessment
Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, suitable for autologous stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed